Overview

• Luke Miels, currently chief commercial officer, was named CEO designate and will take full responsibilities on January 1, 2026.
• Emma Walmsley will leave the board at year-end and remain employed through her notice period until September 30, 2026.
• The board charged the incoming chief with delivering more than £40 billion in annual sales by 2031, a target set as the company contends with US tariff threats and patent expiries.
• Shares rose about 3.5% in early trading following the announcement, signaling a positive initial reception from investors.
• GSK disclosed the successor’s initial pay terms, including a £1.38 million base salary and substantial annual and long‑term incentive opportunities.